View Post

De-escalated neoadjuvant paclitaxel, dual HER2 blockade effective in breast cancer subtype

In Clinical Studies News by Barbara Jacoby

By: Ryan Lawrence From: healio.com A de-escalated, 12-week neoadjuvant treatment regimen of dual HER2 blockade with pertuzumab and trastuzumab plus weekly paclitaxel demonstrated high efficacy among patients with HER2-positive, hormone receptor-negative early breast cancer. Researchers presented the first survival data from the randomized, phase 2 WSG-ADAPT-HR-/HER2+ trial — part of the ADAPT umbrella protocol — during the virtual ASCO Annual …